Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187006410 |
ATIVAN® Tablets 1mg 1,000s |
02/06/2020 |
2554.56 |
34890.72 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187006301 |
ATIVAN® Tablets .5mg 100s |
02/06/2020 |
195.26 |
2666.86 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187006401 |
ATIVAN® Tablets 1mg 100s |
02/06/2020 |
260.83 |
3562.53 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187006501 |
ATIVAN® Tablets 2mg 100s |
02/06/2020 |
415.69 |
5677.56 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187301220 |
MESTINON 60mg /SYRUP (pyridostigmine bromide) 473mL 1 Bottle |
01/09/2020 |
74.41 |
1314.63 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187301030 |
MESTINON 60mg TABLETS 100s (pyridostigmine bromide) |
01/09/2020 |
91.61 |
1618.51 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187301330 |
MESTINON TIMESPAN 180mg TABLETS (pyridostigmine bromide) 30 CT |
01/09/2020 |
52.13 |
920.95 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
66490069110 |
MYSOLINE 250 mg TABLETS, 100s (primidone) |
02/06/2020 |
374.17 |
5110.50 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
66490069010 |
MYSOLINE 50 mg TABLETS, 100s (primidone) |
02/06/2020 |
108.73 |
1485.06 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187305050 |
ONEXTON™ (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/3.75% 50g Pump |
01/09/2020 |
33.55 |
592.71 |
08/05/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187442010 |
PEPCID® (Famotidine) Tablets, 20mg, 100 |
01/09/2020 |
64.29 |
1135.80 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
02/10/2015 |
Marathon Pharmaceuticals, LLC |
286000000 |
None |
Pepcid was acquired as part of a broader portfolio of hospital products from Marathon Pharmaceuticals, LLC in 2015. The product acquisition price was incorporated into the deal overall purchase price. |
309.13 |
309.13 |
2012 |
222.22 |
None |
The product was introduced to the market before acquisition by Valeant Pharmaceuticals North America LLC. (VPNA). The year of introduction and WAC at introduction contained in this report is the only information available to VPNA in the Compendia database . VPNA has no knowledge of the actual date of introduction nor the WAC at introduction. No patent expiration date listed. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187442030 |
PEPCID® (Famotidine) Tablets, 20mg, 30 |
01/09/2020 |
19.29 |
340.75 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
02/10/2015 |
Marathon Pharmaceuticals, LLC |
286000000 |
None |
Pepcid was acquired as part of a broader portfolio of hospital products from Marathon Pharmaceuticals, LLC in 2015. The product acquisition price was incorporated into the deal overall purchase price. |
92.74 |
92.74 |
2012 |
66.67 |
None |
The product was introduced to the market before acquisition by Valeant Pharmaceuticals North America LLC. (VPNA). The year of introduction and WAC at introduction contained in this report is the only information available to VPNA in the Compendia database . VPNA has no knowledge of the actual date of introduction nor the WAC at introduction. No patent expiration date listed. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187444010 |
PEPCID® (Famotidine) Tablets, 40mg, 100 |
01/09/2020 |
124.26 |
2195.32 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
02/10/2015 |
Marathon Pharmaceuticals, LLC |
286000000 |
None |
Pepcid was acquired as part of a broader portfolio of hospital products from Marathon Pharmaceuticals, LLC in 2015. The product acquisition price was incorporated into the deal overall purchase price. |
597.50 |
597.50 |
2014 |
597.50 |
None |
The product was introduced to the market before acquisition by Valeant Pharmaceuticals North America LLC. (VPNA). The year of introduction and WAC at introduction contained in this report is the only information available to VPNA in the Compendia database . VPNA has no knowledge of the actual date of introduction nor the WAC at introduction. No patent expiration date listed. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187444030 |
PEPCID® (Famotidine) Tablets, 40mg, 30 |
01/09/2020 |
37.28 |
658.56 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
02/10/2015 |
Marathon Pharmaceuticals, LLC |
286000000 |
None |
Pepcid was acquired as part of a broader portfolio of hospital products from Marathon Pharmaceuticals, LLC in 2015. The product acquisition price was incorporated into the deal overall purchase price. |
179.24 |
179.24 |
2014 |
179.24 |
None |
The product was introduced to the market before acquisition by Valeant Pharmaceuticals North America LLC. (VPNA). The year of introduction and WAC at introduction contained in this report is the only information available to VPNA in the Compendia database . VPNA has no knowledge of the actual date of introduction nor the WAC at introduction. No patent expiration date listed. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187149825 |
TIMOPTIC? in OCUDOSE? (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.25%, 0.3mL Vial |
01/09/2020 |
25.10 |
443.37 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that acquisition date of Aton Pharma, Inc. which was previously reported as 11/6/2015 was incorrect. The correct acquisition date is 9/1/2010 and therefore, per the reporting requirements, is no longer included. No patent expiration date listed. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2020 |
00187149605 |
TIMOPTIC? in OCUDOSE? (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.50%, 0.3mL Vial |
01/09/2020 |
28.62 |
505.59 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that acquisition date of Aton Pharma, Inc. which was previously reported as 8/9/2015 was incorrect. The correct acquisition date is 9/1/2010 and therefore, per the reporting requirements, is no longer included. No patent expiration date listed. |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2020 |
43068010102 |
Fanapt 1 mg tablets; bottles of 60 |
01/01/2020 |
94.17 |
1271.27 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2020 |
43068010102 |
Fanapt 1 mg tablets; bottles of 60 |
09/14/2020 |
114.41 |
1385.68 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2020 |
43068011002 |
Fanapt 10 mg tablets; bottles of 60 |
01/01/2020 |
185.56 |
2505.01 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2020 |
43068011002 |
Fanapt 10 mg tablets; bottles of 60 |
09/14/2020 |
225.45 |
2730.46 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2020 |
43068011202 |
Fanapt 12 mg tablets; bottles of 60 |
01/01/2020 |
185.56 |
2505.01 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2020 |
43068011202 |
Fanapt 12 mg tablets; bottles of 60 |
09/14/2020 |
225.45 |
2730.46 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2020 |
43068010202 |
Fanapt 2 mg tablets; bottles of 60 |
01/01/2020 |
94.17 |
1271.27 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2020 |
43068010202 |
Fanapt 2 mg tablets; bottles of 60 |
09/14/2020 |
114.41 |
1385.68 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2020 |
43068010402 |
Fanapt 4 mg tablets; bottles of 60 |
01/01/2020 |
94.17 |
1271.27 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2020 |
43068010402 |
Fanapt 4 mg tablets; bottles of 60 |
09/14/2020 |
114.41 |
1385.68 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2020 |
43068010602 |
Fanapt 6 mg tablets; bottles of 60 |
01/01/2020 |
115.87 |
1564.21 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2020 |
43068010602 |
Fanapt 6 mg tablets; bottles of 60 |
09/14/2020 |
140.78 |
1704.99 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2020 |
43068010802 |
Fanapt 8 mg tablets; bottles of 60 |
01/01/2020 |
115.87 |
1564.21 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2020 |
43068010802 |
Fanapt 8 mg tablets; bottles of 60 |
09/14/2020 |
140.78 |
1704.99 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2020 |
43068011304 |
Fanapt 8 tablet titration pack (1mg, 2mg, 4mg, 6mg) |
01/01/2020 |
12.57 |
169.52 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2020 |
43068011304 |
Fanapt 8 tablet titration pack (1mg, 2mg, 4mg, 6mg) |
09/14/2020 |
15.26 |
184.78 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2020 |
43068022001 |
Hetlioz; 20 mg capsules; bottles of 30 |
01/01/2020 |
942.08 |
16643.43 |
07/27/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
12/31/2020 |
43068022001 |
Hetlioz; 20 mg capsules; bottles of 30 |
10/01/2020 |
1997.21 |
18640.64 |
08/29/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025007130 |
CONZIP (tramadol hydrochloride), CAPSULE EXTENDED RELEASE, 100 mg, 30 ct |
01/01/2020 |
25.32 |
341.82 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025007230 |
CONZIP (tramadol hydrochloride), CAPSULE EXTENDED RELEASE, 200 mg, 30 ct |
01/01/2020 |
33.18 |
447.96 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025007330 |
CONZIP (tramadol hydrochloride), CAPSULE EXTENDED RELEASE, 300 mg, 30 ct |
01/01/2020 |
45.90 |
619.62 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025005230 |
CORVITE 150, TABLET, MULTI, 30 ct |
01/01/2020 |
9.58 |
129.32 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025006030 |
CORVITE FE, TABLET, MULTI, 30 ct |
01/01/2020 |
12.60 |
170.11 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025006530 |
DIVIGEL (estradiol gel) GEL, 0.25 mg, 30 ct |
01/01/2020 |
9.97 |
142.89 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025006630 |
DIVIGEL (estradiol gel) GEL, 0.50 mg, 30 ct |
01/01/2020 |
9.97 |
142.89 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025008330 |
DIVIGEL (estradiol gel) GEL, 0.75 mg, 30 ct |
01/01/2020 |
9.97 |
142.89 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025006730 |
DIVIGEL (estradiol gel) GEL, 1.0 mg, 30 ct |
01/01/2020 |
9.97 |
142.89 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025004610 |
LORZONE (chlorzoxazone USP) TABLET, 375 mg, 30 ct |
01/01/2020 |
81.87 |
908.86 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025004710 |
LORZONE (chlorzoxazone USP) TABLET, 750 mg, 30 ct |
01/01/2020 |
91.55 |
1016.26 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025004960 |
OB COMPLETE DHA, SOFTGEL CAPSULE, MULTI, 60 ct |
01/01/2020 |
13.07 |
176.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025004430 |
OB COMPLETE ONE, CAPSULE, MULTI, 30 ct |
01/01/2020 |
13.31 |
179.67 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025005930 |
OB COMPLETE PETITE, SOFTGEL CAPSULE, MULTI, 30 ct |
01/01/2020 |
12.90 |
174.18 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025004330 |
OB COMPLETE PREMIER, TABLET, MULTI, 30 ct |
01/01/2020 |
9.33 |
125.92 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2020 |
68025001010 |
OB COMPLETE PRENATAL, CAPLET, MULTI, 100ct |
01/01/2020 |
16.63 |
224.51 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
Rx0000066 |
ViiV Healthcare |
03/31/2020 |
49702022613 |
TIVICAY TAB 10MG - 30 tablets per bottle |
01/01/2020 |
17.20 |
365.30 |
12/08/2029 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
Rx0000066 |
ViiV Healthcare |
03/31/2020 |
49702022713 |
TIVICAY TAB 25MG - 30 tablets per bottle |
01/01/2020 |
42.99 |
913.24 |
12/08/2029 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
Rx0000066 |
ViiV Healthcare |
03/31/2020 |
49702022813 |
TIVICAY TAB 50MG - 30 tablets per bottle |
01/01/2020 |
85.98 |
1826.47 |
12/08/2029 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |